Development of new drugs has become more common in the recent past due to the advances in the medical field in terms of technology, technical know-how and expertise. Whereas there are many processes, protein formulation development is relatively common. However the process is huddled with uncertainty, restrictions and regulatory frameworks that must be observed.
Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally taken drugs, this usually involves incorporating the drug into a tablet or a capsule. However, a tablet contains a variety of other substances apart from the drug itself, and studies have to be carried out to ensure that the drug is compatible with these other substances
Proteins are known to have complex structures. These structures also have the characteristic of being delicate and easily change when subjected to clinical tests. Hence they require specialized attention to ensure these inevitable changes do not alter the performance of end product. Therefore, adequate resources must be available for these extra care.
Due to the complexity of its structure, and since it is also very delicate, it is practically impossible to extract a pharmaceutical drug containing only the native and pure protein. The process would prove futile due to inefficiencies from the denatured and degraded protein forms. The very process would prove to be too expensive resource wise.
Maintaining the integrity of this protein would be difficult, even with the extraction of pure strands. The shelf life would be drastically reduced and the instability of the same heightened. The processes of handling and transportation and delivery would need to be done with extreme caution. However, the strand would have the advantage of having neither chemical nor physical change.
The structure of this protein itself is a limiting factor. The three dimensional and naturally delicate nature also keep researchers from easily achieving purity and stability of the strand. In this case, the formulations have to be developed with the allowance that there will be inevitable chemical changes in the nature of particular protein.
Safety should always be a concern during the formulation development process. Proper maintenance of this strand will be key to maintain the stature of protein during testing, development, handling and transportation of substance. Appropriate Safety and storage mechanisms should be in place to ensure the viability is preserved.
Various methodical studies need to be carried out to ensure full compliance with regulatory requirements for registration. However, the challenge is that it takes a year or two to collect the results. For efficiency purposes, the commercial formulation should continue in the process of development while preclinical studies and clinical trials are underway.
The intrinsic details of the process of formulation development should be appreciate in regard to the extensive nature of this process. Some of its aspects are not viable nor applicable in real essence and further research is recommended to ensure the untapped nature of this process is determined. Some of these regulations should also be reviewed to give leeway for further intricate research and tests. Much have been done but does not mark the end of it. Researches are ongoing.
Formulation studies involve developing a preparation of the drug which is both stable and acceptable to the patient. For orally taken drugs, this usually involves incorporating the drug into a tablet or a capsule. However, a tablet contains a variety of other substances apart from the drug itself, and studies have to be carried out to ensure that the drug is compatible with these other substances
Proteins are known to have complex structures. These structures also have the characteristic of being delicate and easily change when subjected to clinical tests. Hence they require specialized attention to ensure these inevitable changes do not alter the performance of end product. Therefore, adequate resources must be available for these extra care.
Due to the complexity of its structure, and since it is also very delicate, it is practically impossible to extract a pharmaceutical drug containing only the native and pure protein. The process would prove futile due to inefficiencies from the denatured and degraded protein forms. The very process would prove to be too expensive resource wise.
Maintaining the integrity of this protein would be difficult, even with the extraction of pure strands. The shelf life would be drastically reduced and the instability of the same heightened. The processes of handling and transportation and delivery would need to be done with extreme caution. However, the strand would have the advantage of having neither chemical nor physical change.
The structure of this protein itself is a limiting factor. The three dimensional and naturally delicate nature also keep researchers from easily achieving purity and stability of the strand. In this case, the formulations have to be developed with the allowance that there will be inevitable chemical changes in the nature of particular protein.
Safety should always be a concern during the formulation development process. Proper maintenance of this strand will be key to maintain the stature of protein during testing, development, handling and transportation of substance. Appropriate Safety and storage mechanisms should be in place to ensure the viability is preserved.
Various methodical studies need to be carried out to ensure full compliance with regulatory requirements for registration. However, the challenge is that it takes a year or two to collect the results. For efficiency purposes, the commercial formulation should continue in the process of development while preclinical studies and clinical trials are underway.
The intrinsic details of the process of formulation development should be appreciate in regard to the extensive nature of this process. Some of its aspects are not viable nor applicable in real essence and further research is recommended to ensure the untapped nature of this process is determined. Some of these regulations should also be reviewed to give leeway for further intricate research and tests. Much have been done but does not mark the end of it. Researches are ongoing.
Keine Kommentare:
Kommentar veröffentlichen